KALV Stock Analysis: Buy, Sell, or Hold?
KALV - KalVista Pharmaceuticals, Inc. Common Stock
$27.00
0.01 (0.04%)
▲
5d:
+0.19%
30d:
+1.09%
90d:
+48.03%
BUY
MODERATE Confidence
Analysis Updated: Jun 10, 2026 12:00 AM ET
Earnings: Aug 13, 2026
8d
Get Alerted When KALV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KALV shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: KALV shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: KALV is currently trading at $27.00, which is considered fair based on recent price action.
Technical Outlook: Technically, KALV is in a strong uptrend. The price is currently testing key support at $26.77. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KALV is in a strong uptrend. The price is currently testing key support at $26.77. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
57/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
64.2%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- NEUTRAL: Near Wall St target ($28.60)
Support & Resistance Levels
Support Level
$26.77
Resistance Level
$27.00
Current Trend
Strong Uptrend
Technical data as of
Jun 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.68
Wall Street Target
$28.60
(+5.9%)
Revenue Growth (YoY)
30.7%
Profit Margin
-118.7%
Share & Embed Analysis
Last updated: August 04, 2026 12:12 AM ET
Data refreshes hourly during market hours. Next update: 1:12 AM
Data refreshes hourly during market hours. Next update: 1:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KALV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
14
Sells
Net
INSIDERS SELLING
Recent Transactions
Brian Piekos
SELL
1862 shares
2026-04-17
Nicole Sweeny
SELL
1862 shares
2026-04-17
Paul K Audhya
SELL
2686 shares
2026-04-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$386 | 43 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 54 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
